Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
donor-derived WT1-specific cytotoxic T lymphocytes
- Development stage
- Unknown
- Lead developer
- University of Sydney
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Donor-derived WT1-specific cytotoxic T lymphocytes (CTLs) is an investigational adoptive cell-based immunotherapy developed by the University of Sydney for the prevention of relapse in patients with acute myeloid leukemia (AML) undergoing allogeneic hematopoietic stem cell transplantation (HSCT). The therapy consists of T cells harvested from the transplant donor, which are expanded ex vivo and selected for specificity against the Wilms' tumor 1 (WT1) antigen using CD137+ selection. WT1 is a tumor-associated antigen that is highly overexpressed in myeloid malignancies but has limited expression in healthy tissues, making it a suitable target for post-transplant immunotherapy. In clinical trials such as INTACT-TAA (NCT02895412), these WT1-specific CTLs are administered in a prophylactic regimen, often following the infusion of pathogen-specific T cells (P-CTL), to provide dual protection against leukemic recurrence and opportunistic infections.
- Other names
- WT1-specific T cellsWT-1-specific T cellsWT 1-specific T cellsdonor-derived WT1-specific T cellsdonor-derived WT1-CTL
02
Targets
pMHC-I (Peptide–MHC class I complex)
Beyond the preview
Go deeper on donor-derived WT1-specific cytotoxic T lymphocytes.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on donor-derived WT1-specific cytotoxic T lymphocytes.